Significantly, synthetic bryostatin 1 and analogs SUW201 and SUW229 upregulated CD22 surface expression by ~2-fold in each cell line tested (Fig. 6c, d), further highlighting the potential generality of using PKC modulators for enhancing CD22-targeted cancer immunotherapies. The gene discussed is PRRT2; the disease is cancer.